Vetoquinol SA : Helped by a technical support level

03/17/2023 | 02:26am EDT

long trade Live

Entry price : 81.4€ | Target : 94€ | Stop-loss : 75€ | Potential : 15.48%

The medium term support area around 77.4 EUR should allow Vetoquinol SA shares to re-establish an upward trend in the short term. Investors have an opportunity to buy the stock and target the € 94.

Strengths

• The company is in a robust financial situation considering its net cash and margin position.
• The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
• Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

• With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
• The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
• The company is not the most generous with respect to shareholders' compensation.
• For the past year, analysts have significantly revised downwards their profit estimates.
• The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
• The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart

Subsector Veterinary Drugs

1st jan. Capitalization (M$) Investor Rating VETOQUINOL SA -2.51% 1 087 ZOETIS 12.03% 76 006 ELANCO ANIMAL HEALTH INCORP.. -27.82% 4 335 DECHRA PHARMACEUTICALS PLC -2.60% 3 549 BLUESTAR ADISSEO COMPANY 7.63% 3 472 VIRBAC 27.41% 2 641 CHINA ANIMAL HUSBANDRY INDU.. 20.83% 2 088 WUHAN KEQIAN BIOLOGY CO.,LT.. 16.70% 1 775 JINYU BIO-TECHNOLOGY CO., L.. 18.76% 1 703 PULIKE BIOLOGICAL ENGINEERI.. 3.84% 1 432 TIANJIN RINGPU BIO-TECHNOLO.. 9.78% 1 421

More Results

© MarketScreener.com 2023

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.